Importer of Controlled Substances; Notice Of Registration; Cerilliant Corporation, 21999-22000 [2012-8766]
Download as PDF
<![CDATA[
21999
Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug
Schedule
Etorphine HCl (9059) ...................
Codeine methylbromide (9070) ....
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Heroin (9200) ...............................
Hydromorphinol (9301) .................
Methyldesorphine (9302) ..............
Methyldihydromorphine (9304) .....
Morphine methylbromide (9305) ..
Morphine methylsulfonate (9306)
Morphine-N-oxide (9307) .............
Myrophine (9308) .........................
Nicocodeine (9309) ......................
Nicomorphine (9312) ....................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Acetorphine (9319) .......................
Acetylmethadol (9601) .................
Allylprodine (9602) .......................
Alphacetylmethadol except levoalphacetyl-methadol (9603).
Alphamethadol (9605) ..................
Dioxaphetyl butyrate (9621) .........
Dipipanone (9622) ........................
Ethylmethylthiambutene (9623) ....
Etonitazene (9624) .......................
Etoxeridine (9625) ........................
Furethidine (9626) ........................
Hydroxypethidine (9627) ..............
Ketobemidone (9628) ...................
Levomoramide (9629) ..................
Levophenacylmorphan (9631) ......
Morpheridine (9632) .....................
Noracymethadol (9633) ................
Norlevorphanol (9634) ..................
Normethadone (9635) ..................
Norpipanone (9636) .....................
Phenadoxone (9637) ....................
Phenampromide (9638) ................
Phenoperidine (9641) ...................
Piritramide (9642) .........................
Proheptazine (9643) .....................
Properidine (9644) ........................
Racemoramide (9645) ..................
Trimeperidine (9646) ....................
Phenomorphan (9647) .................
Levo-alphacetylmethadol (9648) ..
Propiram (9649) ...........................
Tilidine (9750) ...............................
Para-Fluorofentanyl (9812) ..........
3–Methylfentanyl (9813) ...............
Acetyl-alpha-methylfentanyl
(9815).
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Phenmetrazine (1631) ..................
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Nabilone (7379) ............................
1–Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
4–Anilino-N-phenethyl-4-piperidine (8333).
Phenylacetone (8501) ..................
Alphaprodine (9010) .....................
Anileridine (9020) .........................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
VerDate Mar<15>2010
16:27 Apr 11, 2012
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 226001
Drug
Schedule
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Isomethadone (9226) ...................
Meperidine (9230) ........................
Meperidine intermediate-B (9233)
Metazocine (9240) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Metopon (9260) ............................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Dihydroetorphine (9334) ...............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Phenazocine (9715) .....................
Piminodine (9730) ........................
Racemethorphan (9732) ..............
Racemorphan (9733) ...................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Tapentadol (9780) ........................
Bezitramide (9800) .......................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration, and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 14, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: April 2, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–8763 Filed 4–11–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice Of Registration; Cerilliant
Corporation
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2321, Cerilliant
Corporation, 811 Paloma Drive, Suite A,
Round Rock, Texas 78665–2402, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Fenethylline (1503) .......................
Gamma
Hydroxybutyric
Acid
(2010).
Alpha-ethyltryptamine (7249) .......
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Drug Schedule.
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
5-Methoxy-N-Ndimethyltryptamine (7431).
E:\FR\FM\12APN1.SGM
12APN1
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
22000
Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Alpha-methyltryptamine (7432) ....
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Benzylpiperazine (7493) ...........
Etorphine (except HCl) (9056) .....
Heroin (9200) ...............................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Pholcodine (9314) ........................
Dextromoramide (9613) ...............
Dipipanone (9622) ........................
Racemoramide (9645) ..................
Drug Schedule.
Trimeperidine (9646) ....................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Poppy Straw Concentrate (9670)
Fentanyl (9801) ............................
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
Dated: April 2, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
[FR Doc. 2012–8766 Filed 4–11–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (OJJDP) Docket No. 1586]
Hearing of the Attorney General’s
National Task Force on Children
Exposed to Violence
Office of Justice Programs
(OJP), Justice.
ACTION: Notice of hearing.
AGENCY:
II
II
II
II
II
II
II
16:27 Apr 11, 2012
Jkt 226001
This is an announcement of
the fourth hearing of the Attorney
General’s National Task Force on
Children Exposed to Violence (the ‘‘task
force’’). The task force is chartered to
provide OJP, a component of the
Department of Justice, with valuable
advice in the areas of children exposed
to violence for the purpose of
addressing the epidemic levels of
exposure to violence faced by our
nation’s children. Based on the
testimony at four public hearings;
comprehensive research; and extensive
input from experts, advocates, and
impacted families and communities
nationwide, the task force will issue a
final report to the Attorney General
presenting its findings and
comprehensive policy recommendations
in the fall of 2012.
DATES: The hearing will take place on
Monday, April 23; Tuesday, April 24;
and Wednesday, April 25, 2012.
ADDRESSES: The hearing will take place
at Wayne State University in the
Bernath Auditorium on the first floor of
the David Adamany Undergraduate
Library, 5155 Gullen Mall, Detroit, MI
48202.
SUMMARY:
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
In reference to drug codes 7360 and
7370, the company plans to import a
synthetic cannabidiol and a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate, 72 FR 3417
(2007). Regarding all other basic classes
of controlled substances, no comments
or objections have been received. DEA
has considered the factors in 21 U.S.C.
823(a) and 952(a) and determined that
the registration of Cerilliant Corporation
to import the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
VerDate Mar<15>2010
Cerilliant Corporation to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Will
Bronson, Designated Federal Official
(DFO), Deputy Associate Administrator,
Child Protection Division, Office of
Juvenile Justice & Delinquency
Prevention, Office of Justice Programs,
810 7th Street NW., Washington, DC
20531. Phone: (202) 305–2427 [note:
this is not a toll-free number]; email:
willie.bronson@usdoj.gov.
FOR FURTHER INFORMATION CONTACT:
This
hearing is being convened to brief the
task force members about the issue of
children’s exposure to violence. The
final agenda is subject to adjustment,
but it is anticipated that on April 23,
there will be an evening session devoted
to public testimony. On April 24, there
will be a morning and afternoon session,
with a break for lunch. The morning
session will likely include welcoming
remarks, introductions, and panel
presentations from invited guests on the
impact of children’s exposure to
violence. The afternoon session will
continue with panel presentations from
invited guests. April 25 will likely be
devoted to a working meeting of task
force members.
This meeting is open to the public.
Members of the public who wish to
attend this meeting must provide photo
identification upon entering the hearing
facility. Access to the meeting will not
be allowed without identification. In
order to best prepare for attendees,
members of the public who wish to
attend this meeting may register with
Will Bronson at defendingchildhood
taskforce@nccdcrc.org in advance of the
meeting. Registrations will be accepted
on a space available basis. Prior
registration is not required to attend this
event, but is required for those who
wish to provide testimony.
Time for public testimony is
scheduled from 5 p.m. to 7 p.m. Eastern
on April 23. Public testimony must be
provided in person and will be limited
to three (3) minutes per witness.
Members of the public who wish to
provide testimony must register with
Will Bronson at defendingchildhoodtask
force@nccdcrc.org by April 20. Please
bring photo identification and allow
extra time prior to the meeting. Persons
interested in communicating with the
task force should submit their written
comments to the DFO at defendingchild
hoodtaskforce@nccdcrc.org, as the time
available will not allow the public to
directly address the task force (except as
provided above) at the meeting.
Anyone requiring special
accommodations should notify Mr.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\12APN1.SGM
12APN1
]]>Agencies
[Federal Register Volume 77, Number 71 (Thursday, April 12, 2012)]
[Notices]
[Pages 21999-22000]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-8766]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice Of Registration;
Cerilliant Corporation
By Notice dated January 6, 2012, and published in the Federal
Register on January 17, 2012, 77 FR 2321, Cerilliant Corporation, 811
Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application
by renewal to the Drug Enforcement Administration (DEA) to be
registered as an importer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
Fenethylline (1503)........................ I
Gamma Hydroxybutyric Acid (2010)........... I
Alpha-ethyltryptamine (7249)............... I
Ibogaine (7260)............................ I
Lysergic acid diethylamide (7315).......... I
Drug Schedule..............................
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
3,4,5-Trimethoxyamphetamine (7390)......... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
5-Methoxy-N-N-dimethyltryptamine (7431).... I
[[Page 22000]]
Alpha-methyltryptamine (7432).............. I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
N-Benzylpiperazine (7493).................. I
Etorphine (except HCl) (9056).............. I
Heroin (9200).............................. I
Morphine-N-oxide (9307).................... I
Normorphine (9313)......................... I
Pholcodine (9314).......................... I
Dextromoramide (9613)...................... I
Dipipanone (9622).......................... I
Racemoramide (9645)........................ I
Drug Schedule..............................
Trimeperidine (9646)....................... I
Tilidine (9750)............................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylphenidate (1724)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Poppy Straw Concentrate (9670)............. II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances for the manufacture of analytical reference
standards.
In reference to drug codes 7360 and 7370, the company plans to
import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No
other activity for this drug code is authorized for this registration.
Comments and requests for hearings on applications to import
narcotic raw material are not appropriate, 72 FR 3417 (2007). Regarding
all other basic classes of controlled substances, no comments or
objections have been received. DEA has considered the factors in 21
U.S.C. 823(a) and 952(a) and determined that the registration of
Cerilliant Corporation to import the basic classes of controlled
substances is consistent with the public interest and with United
States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. DEA has investigated Cerilliant
Corporation to ensure that the company's registration is consistent
with the public interest. The investigation has included inspection and
testing of the company's physical security systems, verification of the
company's compliance with state and local laws, and a review of the
company's background and history. Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above
named company is granted registration as an importer of the basic
classes of controlled substances listed.
Dated: April 2, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-8766 Filed 4-11-12; 8:45 am]
BILLING CODE 4410-09-P
